cell therapies

Oncology

Bridging the innovation gap: Scalable cell therapies, adapti...

Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.

News

J&J takes $2.58bn option to buy in vivo CAR-T firm Sail

Johnson & Johnson has bid for a slice of the in vivo CAR-T category, signing an alliance with Sail Bio that could evolve into a $2.58bn takeover.

News

FDA advisors vote no to Capricor's DMD therapy

FDA advisors voted that Capricor has not shown efficacy for deramiocel in Duchenne muscular dystrophy, due to altered endpoints in its main trial.

News

ASCO26: In vivo CAR-Ts in the spotlight

Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.

Oncology

CAR-NK cell therapies for solid tumours: Closing the gap bet...

CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.

R&D

Biotech’s biggest challenge isn’t scientific, but political ...

We speak to James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy & grandson of FDR

Bridging the innovation gap: Scalable cell therapies, adapti...

J&J takes $2.58bn option to buy in vivo CAR-T firm Sail

FDA advisors vote no to Capricor's DMD therapy

ASCO26: In vivo CAR-Ts in the spotlight

CAR-NK cell therapies for solid tumours: Closing the gap bet...

Biotech’s biggest challenge isn’t scientific, but political ...

GSK showcases positive data with lung cancer drugs at WCLC

Discover a new era of healthcare panel engagement: Grounded ...

cell therapies

Editor's Picks